Latest Hotspot

FDA Greenlights Phase II/III Trial of KPG-121 Coupled with Abiraterone for Initial Therapy in mCRPC

12 June 2024
3 min read

Kangpu Biopharmaceuticals recently revealed that the U.S. Food and Drug Administration has granted approval for a Phase II/III clinical trial investigating KPG-121 in combination with Abiraterone as a first-line therapy for metastatic castration-resistant prostate cancer.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Discovered by Kangpu Biopharmaceuticals, KPG-121 functions as a modulator of the Cereblon (CRBN) E3 ubiquitin ligase complex CRL4CRBN. It is designed to facilitate the rapid ubiquitination and degradation of casein kinase 1α (CK1α) and transcription factors Aiolos (IKZF3) and Ikaros (IKZF1). 

KPG-121 exhibits properties that inhibit cell proliferation and new blood vessel formation, while also boosting immunomodulatory effects. When combined with androgen-receptor antagonists such as enzalutamide, abiraterone acetate, apalutamide, or darolutamide, KPG-121 markedly enhances anti-tumor effectiveness in xenograft models compared to using androgen-receptor antagonists alone.

A Phase I clinical trial conducted in the United States assessed the safety, pharmacokinetics, and therapeutic efficacy of KPG-121 in combination with enzalutamide, abiraterone, or apalutamide for treating patients with both metastatic and non-metastatic castration-resistant prostate cancer. The study found that KPG-121 was generally well tolerated, had a favorable pharmacokinetic profile, and showed promising therapeutic efficacy.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of June 11, 2024, there are 4 investigational drugs for the CRBN and Ubiquitin-protein ligases target, including 13 indications, 4 R&D institutions involved, with related clinical trials reaching 23, and as many as 207 patents.

KPG-121 is a small molecule drug with a focus on addressing neoplasms, urogenital diseases, and hemic and lymphatic diseases. Its active indications include metastatic castration-resistant prostate cancer, castration-resistant prostatic cancer, and myelodysplastic syndromes. With its progression to Phase 2 globally and Phase 1 in China, KPG-121 represents a promising candidate for the treatment of these challenging medical conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline
Latest Hotspot
3 min read
AbbVie Begins Phase 3 Trial for ABBV-383 in Multiple Myeloma, Advancing Oncology Pipeline
12 June 2024
AbbVie has reported that the inaugural patient has received treatment with the experimental ABBV-383 in the CERVINO Phase 3 clinical trial.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 12
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 12
12 June 2024
Jun 12th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Amgen Announces Positive Phase 3 Trial Results for Uplizna® in Treating IgG4-Related Disease
Latest Hotspot
3 min read
Amgen Announces Positive Phase 3 Trial Results for Uplizna® in Treating IgG4-Related Disease
12 June 2024
Amgen announces successful phase 3 trial results for Uplizna® (inebilizumab-cdon) in treating immunoglobulin G4-related disease (IgG4-RD).
Read →
Boston Pharma Presents Data at EASL 2024: BOS-580 Improves Lipid Profiles in MASH Patients
Latest Hotspot
3 min read
Boston Pharma Presents Data at EASL 2024: BOS-580 Improves Lipid Profiles in MASH Patients
12 June 2024
Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.